Showing results (2941-2950 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|September 24, 2022
Long-term response in a patient with adenocarcinoma harboring both common and uncommon EGFR mutationsShinichiro Okauchi, Hiroaki Satoh
Investigational New Drugs|January 5, 2022
Radiosensitizing effect of galunisertib, a TGF-ß receptor I inhibitor, on head and neck squamous cell carcinoma in vitroBernhard J Jank, Teresa Lenz, Markus Haas, et al.
Investigational New Drugs|January 5, 2022
AM22, a novel synthetic microRNA, inhibits the proliferation of colorectal cancer cells by targeting core binding factor subunit β (CBFB)Fanyi Meng, Jiawei Li, Yajing Qiu, et al.
Investigational New Drugs|January 8, 2022
Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancerXuetong Rong, Haiyi Liu, Hongmei Yu, et al.
Investigational New Drugs|June 3, 2011
Reversible posterior leukoencephalopathy syndrome and trastuzumabHiroyasu Kaneda, Isamu Okamoto, Taroh Satoh, et al.
Investigational New Drugs|May 19, 2011
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I studyJens Samol, Malcolm Ranson, Edwina Scott, et al.
Investigational New Drugs|February 1, 1990
Phase II trial of 4' deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council studyC Rose, T E Lad, L J Kilton, et al.
Investigational New Drugs|May 4, 2011
Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancerIsamu Okamoto, Nobuyuki Yamamoto, Kaoru Kubota, et al.
Investigational New Drugs|July 21, 2011
A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XLJung Jin Hwang, Yong Sook Kim, Taelim Kim, et al.
Investigational New Drugs|June 10, 2011
Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitorLih-Ching Hsu, David E Durrant, Ching-Chun Huang, et al.
Pageof 372